Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism.

Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism. Abstract Text:

H KABAT,

Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism. Publishing Authors By Initials

H KABAT,

For similar heterocyclic compounds: heterocyclic compounds, 1-ring: azoles: imidazoles: imidazolidines: hydantoins research abstracts see: heterocyclic compounds: heterocyclic compounds, 1-ring: azoles: imidazoles: imidazolidines: hydantoins research

PUBMED ID PMID:

MEDLINE DATE:

Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Annals of internal medicine

VOLUME: 50

Page Numbers: 1438-48

Journal Abbreviation: Ann. Intern. Med.

ISSN: 0003-4819

DAY: 24

MONTH: Jun

YEAR: 1959

Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372351

Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism. Keywords Mesh Terms:

KEYWORDS: Hydantoins

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism. Information

Substance Name: phenothiazine

Registry Number: 92-84-2

Grant and Affiliation Information for Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism.

AFFILIATION:

Country: Not Available

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ann Intern Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism Related Publications

• A quantitative study of passive anaphylaxis in the guinea pig; the latent period in passive anaphylaxis in its relation to the dose of rabbit antiovalbumin.
• Allergic mechanisms in nervous disease.
• An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations.
• Development of H activity by human blood-group B substance treated with coffee bean alpha-galactosidase.
• Drug therapy of cerebellar ataxia and disorders of the basal ganglia, based on cerebellar-striatal antagonism.
• Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism.
• Immunochemical estimation of the rate of disappearance of transfused gamma globulin from the blood in two cases of hypoproteinemia.
• Immunochemical studies on blood groups; the methylpentose contents of hog and human blood group A and O substances and their relationship to cross-reactivity with type XIV antipneumococcus horse serum.
• Permanente Foundation medical bulletin
• Permanente Foundation medical bulletin
• Permanente Foundation medical bulletin
• Pillars Article: An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity. J. Exp. Med. 1970. 132: 211-250.
• REM sleep reduction, mood regulation and remission in untreated depression.
• Size and heterogeneity of the combining sites on an antibody molecule.
• Spasticity; its nature and treatment.
• Sterilizing techniques with ethylene oxide.
• Studies on neuromuscular dysfunction; new principles of neuromuscular reeducation.
• The effect of adrenocorticotrophic hormone and X-ray on the amount of circulating antibody.
• The role of drugs in the treatment of cerebral palsy.
• The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment.
• [Calcium channel blockers in the treatment of arterial hypertension]